known HIV,

immunomodulatory drugs,

malignancy (other than basal cell or squamous cell carcinoma, carcinoma in situ of the cervix, or early stage prostate cancer),

active infection in the 2 weeks prior to study injection,

serious S. aureus infection within the last 3 months prior to injection,

use of investigational drugs, vaccines or devices within the prior 30 days,

hypersensitivity to components of StaphVAX

Evaluation of Consistency of StaphVAX Manufacturing Lots